We are live on ! Find out more

225 hedge funds and large institutions have $2.86B invested in Insmed in 2022 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 101 increasing their positions, 61 reducing their positions, and 45 closing their positions.

New
Increased
Maintained
Reduced
Closed

66% more repeat investments, than reductions

Existing positions increased: 101 | Existing positions reduced: 61

33% more funds holding in top 10

Funds holding in top 10: 34 (+1)

3% more capital invested

Capital invested by funds: $2.78B → $2.86B (+$81M)

2% less call options, than puts

Call options by funds: $3.22M | Put options by funds: $3.29M

2.97% less ownership

Funds ownership: 108.86%105.88% (-3%)

5% less funds holding

Funds holding: 238225 (-13)

22% less first-time investments, than exits

New positions opened: 35 | Existing positions closed: 45

Holders
225
Holders Change
-13
Holders Change %
-5.46%
% of All Funds
3.62%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.06%
New
35
Increased
101
Reduced
61
Closed
45
Calls
$3.22M
Puts
$3.29M
Net Calls
-$72K
Net Calls Change
-$1.87M

INSM Hedge Fund Activity: Q4 2022 in Review

225 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Insmed (INSM) for Q4 2022, worth a combined $2.86B — up 2.9% from $2.78B a quarter earlier.

Sellers outnumbered buyers: 45 funds closed out of INSM and 35 opened new positions — a net loss of 10 holders — while 61 trimmed existing stakes and 101 added.

The largest buyer was Deep Track Capital, opening a new position worth an estimated $82.4M. The largest seller was Janus Henderson Group, cutting an estimated $74.3M.

  • 225 institutional investors held Insmed (INSM) as of Q4 2022, down from 238 in Q3 2022.
  • Funds reported $2.86B of Insmed stock for Q4 2022, up 2.9% quarter-over-quarter.
  • 35 funds opened new Insmed positions in Q4 2022 and 45 closed out, a net change of -10 holders.
  • The largest Insmed buyer in Q4 2022 was Deep Track Capital, an estimated $82.4M added.
  • The largest Insmed seller in Q4 2022 was Janus Henderson Group, an estimated $74.3M sold.

Based on aggregated 13F filings for Q4 2022.